Common questions about Proginova (FAQ)
Q: Does Proginova contain only estrogen, or are other hormones included?
A: Official documentation describes Proginova as a single-component Estrogen therapy. It contains the active ingredient estradiol valerate, which is a precursor of the hormone estradiol. The official product information does not list other active hormones in its composition.
Q: Can Proginova cause changes in body weight, and if so, how?
A: Official safety labeling lists changes in body weight as a common documented adverse reaction experienced by users of Proginova. However, the official prescribing information does not detail the specific biological mechanism by which this change occurs.
Q: Does Proginova interact with common pain relievers or supplements?
A: The official interaction profile lists specific enzyme inducers, like certain anti-seizure medicines, and the herbal product St. John’s Wort, which can reduce estrogen concentration. Information regarding interactions with many common, non-specific pain relievers or general supplements is not typically detailed in the primary regulatory documentation.
Q: Are there any specific foods or drinks, like alcohol, that interact with Proginova?
A: Official product information documents that Grapefruit juice is an inhibitor that can increase estrogen exposure. Additionally, official safety notes state that excess intake of alcohol during hormone replacement therapy (HRT) is cited as having an influence on the treatment.
Q: Is it safe to use Proginova if I have a history of migraines or severe headaches?
A: According to official product information, a history of migraine is a disorder that necessitates close medical supervision during therapy. It is a regulatory constraint that requires immediate discontinuation of the medicine if migrainous or unusually severe headaches occur for the first time.
Q: Is Proginova suitable for long-term use, or is it only intended for a short time?
A: The general regulatory principle for all hormone replacement therapy is to use the lowest effective dose for the shortest necessary duration. Official documents note that the risk of certain serious adverse reactions is associated with the duration of use.
Q: Can Proginova be used by women who have had a hysterectomy?
A: Proginova can be used by women who do not have an intact uterus (post-hysterectomy). These patients do not require the addition of a progestogen to their regimen, as this requirement is specified only for women with an intact uterus.
Q: Does Proginova have a known interaction with smoking or being overweight?
A: The official interaction profile states that stopping nicotine (smoking) during treatment may affect the dosage requirement. Obesity is cited in some regulatory contexts as a known pre-existing risk factor for increased thromboembolic or cardiovascular events.
Q: Why does Proginova sometimes affect liver function test results?
A: Official safety information notes that the medicine is formally restricted in cases of severe active liver disease. The medicine should be discontinued if signs of severe upper abdominal complaints or liver enlargement occur, and liver function should be monitored.
Q: Can Proginova be used by women with certain types of fibroids in the womb?
A: Use is permitted, but the official regulatory profile requires close monitoring for patients with uterine fibroids (leiomyoma). This monitoring is required due to the risk of the condition being made worse by the medicine.
Q: Are there research studies comparing the safety profile of Proginova to other estrogens?
A: Official evidence summaries indicate that data on long-term outcomes and evidence comparing outcomes to other study interventions is lacking in certain research contexts. The primary focus of the regulatory data is on the safety profile of Proginova itself.
Q: What kind of abnormal vaginal bleeding should be reported while on Proginova?
A: Official guidance advises that frequent bleeding irregularities or persistent bleeding should be discussed with a healthcare provider. This is important to rule out potential health issues.
Q: Does Proginova affect blood pressure, and should I monitor it closely?
A: Small increases in blood pressure have been reported in women taking hormone replacement therapy. The medicine is typically used with caution in patients with pre-existing hypertension (high blood pressure), which may necessitate monitoring.
Q: Does Proginova interact with medications for high cholesterol or triglycerides?
A: The official profile advises close monitoring for patients with hypertriglyceridemia (high triglycerides). Estrogens may also cause adverse lipid changes, including elevations in triglyceride levels, particularly in these patients.
Q: What are the general research findings regarding long-term use of estrogen-only HRT?
A: Studies have explored long-term changes, up to five years or more. However, the official evidence summaries indicate that data on long-term symptom patterns are limited. Official information notes that the risk of serious adverse events is duration-dependent.
Q: Does Proginova affect sleep disturbances related to menopause?
A: Official prescribing information indicates that Proginova may relieve symptoms associated with estrogen deficiency, such as sleep disturbances and hot flushes (vasomotor symptoms).
Q: What does 'unopposed estrogen' mean in the context of Proginova and endometrial risk?
A: The concept relates to estrogen therapy used without a progestogen. Regulatory documents require women with an intact uterus to incorporate a progestogen to balance hormonal activity and reduce the risk of endometrial hyperplasia and cancer.
Q: Are there known effects of Proginova on headaches that are not migraines?
A: Headache is listed as a frequently reported adverse reaction to the medicine. Official documents also state that the medicine may relieve headaches associated with estrogen deficiency.
Q: Can Proginova be used by patients with a history of endometriosis?
A: Use is permitted, but the regulatory profile advises close monitoring for patients with a history of endometriosis due to the risk of the condition becoming worse.
Q: How does the risk profile of Proginova change for women over 65?
A: The regulatory profile advises caution when initiating therapy at or above 65 years of age. It is also documented that there is an increased risk of developing probable dementia in women aged 65 years and older.
Q: Is Proginova used to treat symptoms of perimenopause or only postmenopause?
A: Official documentation indicates the medicine is used to treat estrogen deficiency symptoms that occur during the climacteric (the phase leading up to and including menopause) and after the cessation of monthly bleeding.
Q: Is it normal to experience spotting or breakthrough bleeding when starting Proginova?
A: Changes in vaginal bleeding pattern including spotting are listed as side effects reported in users of various oral HRT preparations. These changes may occur, particularly during the first few months of treatment.
Q: Does Proginova interact with thyroid medication like Levothyroxine?
A: Official data and medical literature indicate that oral estrogen therapy may increase the dosage requirements of thyroid hormones by increasing thyroid-binding globulin levels. This effect is noted in the literature, often necessitating dose adjustments or extra monitoring when co-administered.
Q: Does Proginova help with symptoms like depressive moods or irritability associated with menopause?
A: Official documentation indicates that Proginova may relieve symptoms associated with estrogen deficiency, such as depressive moods and nervous irritability.
Q: Does Proginova have any effect on skin or hair quality?
A: Official pharmacological properties note that the active ingredient may have a positive effect on skin collagen content and skin thickness and can retard the process of skin wrinkling. Hair loss and excessive hairiness are also documented as reported side effects.
Q: Can Proginova cause or worsen mood swings or feelings of anxiety?
A: Official safety information lists feeling depressed and/or anxious as documented adverse reactions under the Psychiatric disorders category. Mood swings are also listed as a symptom of a premenstrual-like syndrome that may occur.
Q: Why are regular check-ups, like breast and pelvic exams, required when using Proginova?
A: Official safety notes state that regular gynaecological check-ups should be carried out at about 6-month intervals. This is due to the documented increased incidence of certain cancers (breast, endometrial) associated with HRT use.
Q: Is it possible for Proginova to affect vision or cause contact lens intolerance?
A: Official safety information lists visual disturbances (such as partial or complete loss of vision) and intolerance to contact lenses under the category of eye disorders as documented side effects.
Q: What are the signs of a serious reaction or blood clot that require immediate medical attention?
A: Official documents list warning signs such as unusual pains or swelling of your arms or legs, sudden shortness of breath, coughing blood, or fainting. These symptoms are listed as signs that warrant urgent consultation with a healthcare provider.
Q: Can Proginova be used if I have a history of gallstones?
A: Official safety information notes that the use of hormone replacement therapy may increase the risk of gall bladder disease. Diseases of the liver or gallbladder are listed as conditions requiring strict medical supervision.
Q: Is it correct that Proginova is not considered a contraceptive?
A: Official information states that ovulation is not inhibited during the use of Proginova. Therefore, it does not act as a contraceptive.
Q: Why do some people report anxiety or depression when taking Proginova?
A: Official documentation lists feeling depressed and/or anxious as documented adverse reactions under the Psychiatric disorders category.
Q: Is Proginova used to help treat low libido related to hormone changes?
A: Official documentation for the climacteric syndrome lists loss of libido as a symptom associated with estrogen deficiency that hormone replacement therapy is used to alleviate.
